Kantar Health Blog

  • Buparlisib may be a BELLE only for select patients

    by Arnold DuBell | Dec 14, 2015
    Arnold DuBell
    Oncology Conference Insight: SABCS 2015 --- In the past, patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer were treated with single-agent hormonal agents – either tamoxifen if the patient is premenopausal or an aromatase inhibitor (AI) if she is postmenopausal.
    Continue Reading > | Go comment! | Share
  • Veni, Vedi, Vene? Venetoclax hopes to conquer CLL

    by Stephanie Hawthorne | Dec 8, 2015
    Stephanie Hawthorne
    Oncology Conference Insight --- ASH 2015: Treatment of chronic lymphocytic leukemia (CLL) has enjoyed somewhat of a renaissance in the past couple of years. Until recently, therapy for both front-line and relapsed disease usually consisted of a Rituxan-based regimen often in combination with chemotherapy agents such as fludarabine or Treanda.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2015 --- The field of immunotherapy in oncology has exploded in the last few years, particularly in the case of immune checkpoint inhibitors, which block the immune system’s “brakes” by inhibiting either CTLA-4, PD-L1, PD-L2 or PD-1 (although inhibitors of other immune checkpoint molecules are also in early stages of development).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2015 --- Cytarabine-based intensive chemotherapy remains standard of care for patients with acute myeloid leukemia (AML); however, about 70% of patients will relapse within five years of initial therapy, thus highlighting the need for development of more efficacious regimens.1 While therapy has traditionally consisted of a “one-size-fits-all” concept, it is better appreciated that AML is a rather heterogeneous disease comprising various subtypes with complex genetic and chromosomal changes.
    Continue Reading > | Go comment! | Share
  • The Landscape of Cancer: Immunotherapy Shining Through

    by Stephanie Hawthorne | Oct 7, 2015
    Stephanie Hawthorne
    Immunotherapy is shining through in the crowded space that is oncology, over 6,000 oncology drugs are in development with more than 2,400 different mechanisms of action (MOAs). Immunotherapies have started to enter the mainstream, with many headlines touting immunotherapy as the Holy Grail of cancer treatment.
    Continue Reading > | Go comment! | Share